|
|
|
 |
 |
|
       |
|
|
|
News | October 16, 2000  Northwest Biotherapeutics Awards Kidney Cancer Target Manufacturing Contract Meriden, CT, October 16, 2000 - Northwest Biotherapeutics, Inc. announced today that it has selected Protein Sciences Corporation, Meriden, Connecticut to develop a high yield expression vector for production of a proprietary kidney cancer-specific protein as a component of a new treatment for renal cell carcinoma. The terms of the agreement were not disclosed. "This represents an important next step in extending our company's proprietary dendritic cell-based immunotherapy, DCVax™, to other cancers with limited treatment options", states Alton L. Boynton, Ph.D., Northwest Biotherapeutics' Executive Vice President and Chief Science Officer. "Protein Sciences will apply GeneXpress®, its program for rapidly developing cost-effective clinical quality recombinant protein expression systems, to facilitate the production of material needed to prepare our DCVax™ kidney cancer vaccine for human clinical trials."DCVax™ is currently being evaluated as a treatment for late-stage prostate cancer at M.D. Anderson Cancer Center, Houston and the University of California, Los Angeles (UCLA) where patients are continuing to be recruited. Northwest Biotherapeutics is also continuing pre-clinical evaluation of DCVax™ as a treatment for non-small cell lung cancer and for glioblastoma, a lethal form of brain cancer. Protein Sciences Corporation is a privately held company founded in 1983 that employs its GeneXpress® program to address the needs of pharmaceutical and biotechnology companies by reducing the time, risk and cost of moving product candidates into clinical trials. For additional information on Protein Sciences, visit the Company's web site at www.proteinsciences.com. Northwest Biotherapeutics, Inc. is a privately held company founded in 1996 to develop and commercialize products and services to improve care for prostate and other cancer patients. Northwest Biotherapeutics recently announced the completion of its new corporate headquarters, laboratory and state-of-the-art cell processing facility in Bothell, Washington. It intends to use its expanded capacity to support larger clinical evaluations of DCVax™. For additional information on Northwest Biotherapeutics, visit the Company's web site at www.nwbio.com |
|
|
|
||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
